Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study

Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study

Aims: This study aimed to develop an AI algorithm for automated HER2 scoring in urothelial bladder cancer (UBCa) and assess the interobserver agreement using both manual and AI-assisted methods based on breast cancer criteria. Methods and Results: We utilized 330 slides from two institutions for ini...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aoling Huang, Yizhi Zhao, Feng Guan, Hongfeng Zhang, Bin Luo, Ting Xie, Shuaijun Chen, Xinyue Chen, Shuying Ai, Xianli Ju, Honglin Yan, Lin Yang, Jingping Yuan
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Computational and Structural Biotechnology Journal
Subjects:	Artificial intelligence Bladder cancer HER2-low Heterogeneity
Online Access:	http://www.sciencedirect.com/science/article/pii/S2001037024003271
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Double trouble: how c-MET and HER2 fuel bladder cancer progression
by: E. M. Naguib, et al.
Published: (2024-12-01)

Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy
by: Yatong Chen, et al.
Published: (2025-01-01)

Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
by: Engy Mohammed Naguib, et al.
Published: (2024-12-01)

The Evaluation of CD10 and HER2 Immunohistochemical Markers in Urothelial Carcinoma of Urinary Bladder
by: Khalid W. Abdulfattah Khattab, et al.
Published: (2024-12-01)

Clinical significance of HER2 in urothelial carcinoma and analysis of its correlation with glycolytic metabolic characteristics
by: Andong Guo, et al.
Published: (2024-12-01)

Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer
by: Wang H, et al.
Published: (2024-11-01)

Lactylation Modification as a Promoter of Bladder Cancer: Insights from Multi-Omics Analysis
by: Yipeng He, et al.
Published: (2024-11-01)

Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
by: Jing-Jing Liu, et al.
Published: (2024-11-01)

The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder
by: Meftun Culpan, et al.
Published: (2021-12-01)

Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer
by: Shuo Wang, et al.
Published: (2024-11-01)

Risk factors for upper tract urothelial recurrence following local excision of bladder cancer
by: Ning Lin, et al.
Published: (2018-08-01)

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
by: Whi-An Kwon, et al.
Published: (2025-01-01)

Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis
by: Youngheun Jo, et al.
Published: (2023-07-01)

Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives
by: Irene Testi, et al.
Published: (2024-11-01)

Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma
by: Xiaobin Chen, et al.
Published: (2024-11-01)

The Prognostic Impact of Angiolymphatic Invasion in Bladder Urothelial Carcinoma Patients Undergoing Radical Cystectomy
by: Jin Hyuck Kim, et al.
Published: (2023-03-01)

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions
by: Dimitrios Papageorgiou, et al.
Published: (2024-12-01)

Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges
by: Marie Brevet, et al.
Published: (2024-12-01)

CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course
by: Henning Plage, et al.
Published: (2024-06-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Control of nerve-mediated and urothelial ATP release by a protein kinase G-dependent pathway in the mouse bladder
by: Basu Chakrabarty, et al.
Published: (2024-12-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

Solitary fibrous tumor of the bladder: A rare cause of bladder outlet obstruction in an adult male
by: Návan vanJaarsveld, et al.
Published: (2025-01-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways
by: Gizem Yayli, et al.
Published: (2024-11-01)

Clinical Effect of "RuningⅡ" and Massage along Meridians Treatment on Patients with HER-2 Over-expressing Breast Cancer in Postoperative Rehabilitation Period
by: Shengfang HU, et al.
Published: (2016-02-01)

A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance
by: Arjun Guduguntla, et al.
Published: (2025-01-01)

Pitfalls of frozen section diagnosis in ureter margin evaluation of plasmacytoid urothelial carcinoma of urinary bladder
by: Ji Min Kim, et al.
Published: (2024-11-01)

State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes
by: Elisa Tassinari, et al.
Published: (2025-12-01)

Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC)
by: Laila Schneidewind, et al.
Published: (2025-02-01)

Enhancing antitumor activity of herceptin in HER2-positive breast cancer cells: a novel DNMT-1 inhibitor approach
by: Li-li Ren, et al.
Published: (2024-11-01)

Neurofibroma of bladder: A case report and literature review
by: Zhipeng Yan, et al.
Published: (2025-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
by: Yoonwon Kook, et al.
Published: (2024-11-01)

Percutaneous cystolitholapaxy in reconstructed bladder through the bowel segment
by: Razan Khalid Almesned, et al.
Published: (2025-01-01)

Study of Arabic Translation of Her Eyes According to Bremen’s Deconstructive Method
by: Tayebeh Amirian
Published: (2021-04-01)

Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial
by: Federica Sordelli, et al.
Published: (2025-01-01)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

Role of anoikis-related gene RAC3 in prognosis, immune microenvironment, and contribution to malignant behavior in vitro and in vivo of bladder urothelial carcinoma
by: Yusong Zhou, et al.
Published: (2024-11-01)

Indication and functional outcome of orthotopic neo-bladder reconstruction following radical cystectomy for bladder cancers in a specialist hospital in north-west Cameroon
by: Tagang Titus Ngwa-Ebogo, et al.
Published: (2024-12-01)